⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for mammary carcinoma, human

Every month we try and update this database with for mammary carcinoma, human cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer SurvivorsNCT05364450
Breast Neoplasm
Breast Cancer
Breast Carcinom...
Malignant Neopl...
Cancer of Breas...
Mammary Neoplas...
Human Mammary C...
Malignant Tumor...
Mammary Cancer
Mammary Carcino...
Anxiety
Fear
Enhanced Usual ...
Acceptance Comm...
Cognitive Behav...
18 Years - 99 YearsIndiana University
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsNCT04521686
Cholangiocarcin...
Chondrosarcoma
Glioma
Any Solid Tumor
LY3410738
Gemcitabine
Cisplatin
Durvalumab
18 Years - Eli Lilly and Company
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)NCT03157128
Non-Small Cell ...
Medullary Thyro...
Colon Cancer
Any Solid Tumor
LOXO-292
12 Years - Eli Lilly and Company
Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer SurvivorsNCT05364450
Breast Neoplasm
Breast Cancer
Breast Carcinom...
Malignant Neopl...
Cancer of Breas...
Mammary Neoplas...
Human Mammary C...
Malignant Tumor...
Mammary Cancer
Mammary Carcino...
Anxiety
Fear
Enhanced Usual ...
Acceptance Comm...
Cognitive Behav...
18 Years - 99 YearsIndiana University
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsNCT04521686
Cholangiocarcin...
Chondrosarcoma
Glioma
Any Solid Tumor
LY3410738
Gemcitabine
Cisplatin
Durvalumab
18 Years - Eli Lilly and Company
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsNCT03899792
Medullary Thyro...
Infantile Myofi...
Infantile Fibro...
Papillary Thyro...
Soft Tissue Sar...
LOXO-292
6 Months - 21 YearsEli Lilly and Company
Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer SurvivorsNCT05364450
Breast Neoplasm
Breast Cancer
Breast Carcinom...
Malignant Neopl...
Cancer of Breas...
Mammary Neoplas...
Human Mammary C...
Malignant Tumor...
Mammary Cancer
Mammary Carcino...
Anxiety
Fear
Enhanced Usual ...
Acceptance Comm...
Cognitive Behav...
18 Years - 99 YearsIndiana University
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsNCT03899792
Medullary Thyro...
Infantile Myofi...
Infantile Fibro...
Papillary Thyro...
Soft Tissue Sar...
LOXO-292
6 Months - 21 YearsEli Lilly and Company
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: